Diaverum withdraws initial public offering
Following the announcement of its intention to float on 16 November 2020, Diaverum AB (publ.) (“Diaverum” or the “Company”), a leading global dialysis provider, today announces it will not proceed with the planned listing on Nasdaq Stockholm.
Martin Dunn, member of the board of directors of Diaverum and partner at Bridgepoint, commented: “Despite strong interest from potential investors, including several high quality pension funds, who recognised Diaverum’s impressive underlying performance and ability to grow both revenues and earnings year on year, indications received did not fully reflect the fundamental value of the business. For this reason, we have decided to withdraw the IPO.”
Diaverum CEO Dimitris Moulavasilis commented: “Diaverum is a resilient business with a healthy exposure to high-growth markets and great execution capabilities to continue delivering future growth with attractive margins. We welcome the continued support from Bridgepoint as a long-term investor.”
For more information, please contact:
Niklas Alm, Head of IR: +46708244088
Bruno Polizio, Director of Global Communications: +447874853405
About Diaverum
Diaverum provides life enhancing renal care to patients with Chronic Kidney Disease (CKD), enabling them to live fulfilling lives. Diaverum is a leading global provider in renal care services and the largest independent provider in Europe, and we help some 39,000 patients with 6 million treatments annually. Our focus is haemodialysis, but we offer a portfolio of treatments ranging from preventive care, peritoneal dialysis and home care to coordination of patients’ comorbidities and transplantation services.
CKD is a global and escalating challenge today affecting about 10% of the world’s adult population. It’s primarily caused by lifestyle diseases such as diabetes, and the prevalence is increasing in particular in developing countries. CKD disproportionately affects low income individuals and we ensure that our clinics are a safe and familiar space where all our patients are made to feel welcome.
Diaverum’s vision is to transform renal care, to offer the highest quality of care and empower patients to live a fulfilling life. We work together with payers to reduce total cost of care while partnering with local communities to educate around health and the value of prevention.
At the centre of what we do is our standardised, proprietary care delivery model, enabled by a continuously evolving digital infrastructure. We strive to ensure superior medical outcomes exceeding those demanded by national healthcare systems and we support patients by improving personalized care, ease of use and new services through technology.
Diaverum employs more than 11,000 employees and operates more than 421 clinics in 22 countries globally. Diaverum has its head office in Malmö, Sweden.